The disclosure relates to novel .omega.-pentanor prostaglandin E analogs bearing a 4- or 5-membered O or S hetero-ring as 15-substituent, for example 15-(3-butyloxetan-3-yl)-ll.alpha.,15-dihydroxy-9-oxo-16,17,18,19,20-pentanor-5-cis,13-trans-prostadienoic acid, which are useful as inhibitors of gastric acid production in mammals, together with pharmaceutical and veterinary compositions containing such compounds, and a method of using such compounds to inhibit gastric acid production in mammals.
展开▼
